Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 66
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07063888 - Phase 1/2Taking peopleCRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
- Where
- Beijing
- Age
- 16 years to 85 years
- People
- 90
- Run by
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
See details and how to joinNCT07053488 - No phaseEnrolling by invitationThe Efficacy of Sequential RT After Triple Therapy for uHCC
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Fujian Provincial Hospital
See details and how to joinNCT07052448 - Phase 2Taking peopleLenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Where
- Shanghai
- Age
- 18 years and over
- People
- 146
- Run by
- Fudan University
See details and how to joinNCT07047586 - Phase 1/2Taking peopleClinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Shanghai Public Health Clinical Center
See details and how to joinNCT03093688 - Phase 2Taking peopleJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Where
- Beijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- Age
- 18 years and over
- People
- 72
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06954467 - Phase 2Taking peopleA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 46
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06978114 - No phaseNot yet taking people in ChinaHAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 28
- Run by
- RenJi Hospital
See details and how to joinNCT07045558 - No phaseEnrolling by invitationAI-Driven Quantitative Decision and Surgical Planning System for Liver Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 300
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07042841 - No phaseTaking peopleD-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 37
- Run by
- Fujian Provincial Hospital
See details and how to joinNCT06643208 - Phase 1Not yet taking people in ChinaA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 66
- Run by
- Shanghai Bao Pharmaceuticals Co., Ltd.
See details and how to joinNCT07036185 - Phase 1Taking peoplePIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07018518 - Phase 2Taking peopleSequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 60
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07025174 - No phaseTaking peopleBile Omics for Diagnosing Indeterminate Biliary Strictures
- Where
- Shanghai
- Age
- 18 years to 90 years
- People
- 260
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07007832 - No phaseTaking peopleHead-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
- Where
- Zhongshan
- Age
- 35 years and over
- People
- 4,500
- Run by
- Zhongshan People's Hospital, Guangdong, China
See details and how to joinNCT07010198 - No phaseNot yet taking people in ChinaComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Where
- Beijing, Changchun, Chongqing, Handan, Harbin, Jinan, Qingdao, Tianjin, Wuhan, Xi'an, Xishuangbanna Dai Autonomous Prefecture
- Age
- 18 years to 75 years
- People
- 1,389
- Run by
- Peking University People's Hospital
See details and how to joinNCT07010588 - Phase 2Not yet taking people in ChinaIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
- Where
- Beijing
- Age
- 18 years to 79 years
- People
- 54
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07007728 - No phaseNot yet taking people in ChinaReal-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
- Where
- Anfu, Ankang, Anning, Anqing, Anshan, Anyue, Baise City, Baoding, Baotou, Beihai, Beijing, Bengbu, Benxi, Bihua, Binzhou, Bozhou, Cangzhou, Changchun, Changji, Changle, Changxing, Changzhi, Changzhou, Chaoyang, Chengdu, Chifeng, Chizhou, Chuzhou, Dali, Dalian, Dandong, Daqing, Datong, Donggang, Dongguan, Dongtai, Dongying, Enshi, Ezhou, Fengcheng, Fenyang, Foshan, Fuxin, Fuyang, Fuzhou, Ganzhou, Gaomi, Guangzhou, Guilin, Haikou, Hailin, Hami, Handan, Hangzhou, Hanzhong, Harbin, Hebei, Hefei, Hegang, Heihe, Heilongjiang, Hengshui, Hetian, Heze, Hezhou, Hohhot, Huai'an, Huainan, Huangshan City, Huangshi, Hubei, Huozhou, Jiamusi, Ji’an, Jiangmen, Jianping, Jiaozhou, Jiexiu, Jilin City, Jimo, Jinan, Jincheng, Jingzhou, Jinhua, Jining, Jinxian, Jinzhong, Jinzhou, Jiujiang, Jixi, Junxian, Karamay, Kunming, Laixi, Laizhou, Lanzhou, Lianyungang, Linfen, Linkou, Linxia, Linyi, Lishui, Liuzhou, Longnan, Longyan, Lu'an, Lüliang, Ma’anshan, Macheng, Maoming, Meishan, Mudanjiang, Nanchang, Nanchong, Nangong, Nanjing, Nanning, Nanping, Nantong, Neimeng, Ningbo, Ningcheng, Ordos, Panjin, Pingdu, Pingliang, Pingxiang, Pingyang, Putian, Qingdao, Qingyuan, Qingzhou, Qinhuangdao, Qinzhou, Qiqihar, Quanzhou, Rizhao, Rui’an, Sanming, Shandong, Shangcheng, Shanghai, Shangli, Shangrao, Shawan, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Shouguang, Sichuan, Songyuan, Suqian, Suzhou, Tai’an, Taihe, Taiyuan, Taizhou, Tangshan, Tengzhou, Tianjin, Tongjiang, Tongliao, Tongling, Ürümqi, Weifang, Weihai, Wenzhou, Wu’an, Wuhai, Wuhan, Wuwei, Wuxi, Wuzhou, Xiamen, Xi'an, Xi’an, Xiaogan, Xingtai, Xining, Xinjiang, Xintai, Xiushui, Xizang, Xuancheng, Xuzhou, Yanan, Yanbian, Yancheng, Yangquan, Yangzhou, Yantai, Yibin, Yichang, Yichun, Yinchuan, Yingkou, Yingtan, Yining, Yizheng, Yulin, Yuncheng, Zaozhuang, Zhangjiakou, Zhanjiang, Zhenjiang, Zhongshan, Zibo, Zigong, Zouping
- Age
- 30 years and over
- People
- 1,500
- Run by
- Peking University First Hospital
See details and how to joinNCT07007286 - Phase 2Taking peopleClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 25
- Run by
- Liu Huang
See details and how to joinNCT06199895 - No phaseEnrolling by invitationAdjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma(AICRC)
- Where
- XiAn
- Age
- 18 years to 70 years
- People
- 10
- Run by
- Hengchao Yu
See details and how to joinNCT06997913 - No phaseTaking peopleGemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment (BTC-IM-1)
- Where
- Shanghai
- Age
- 18 years and over
- People
- 100
- Run by
- Fudan University
See details and how to joinNCT06988592 - Phase 1/2Taking peoplePersonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Zhejiang University
See details and how to joinNCT06995105 - No phaseTaking peopleEvaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
- Where
- Beijing
- Age
- 18 years to 85 years
- People
- 99
- Run by
- Peking University Third Hospital
See details and how to joinNCT06277531 - Phase 2Not yet taking people in ChinaIvonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06993025 - Phase 1/2Not yet taking people in ChinaHepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06741020